These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26178881)

  • 1. Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.
    Blattmann C; Oertel S; Thiemann M; Dittmar A; Roth E; Kulozik AE; Ehemann V; Weichert W; Huber PE; Stenzinger A; Debus J
    Radiat Oncol; 2015 Jul; 10():146. PubMed ID: 26178881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
    Blattmann C; Oertel S; Ehemann V; Thiemann M; Huber PE; Bischof M; Witt O; Deubzer HE; Kulozik AE; Debus J; Weber KJ
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):237-45. PubMed ID: 20646843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.
    Blattmann C; Thiemann M; Stenzinger A; Christmann A; Roth E; Ehemann V; Debus J; Kulozik AE; Weichert W; Huber PE; Oertel S; Abdollahi A
    Strahlenther Onkol; 2013 Nov; 189(11):957-66. PubMed ID: 23801068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
    Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
    J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
    Duo J; Ma Y; Wang G; Han X; Zhang C
    DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of radiation response by histone deacetylase inhibition.
    Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
    Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
    Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
    Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
    J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
    Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
    Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
    Knutson AK; Welsh J; Taylor T; Roy S; Wang WL; Tenniswood M
    Oncol Rep; 2012 Mar; 27(3):849-53. PubMed ID: 22159450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
    Kuo WY; Wu CY; Hwu L; Lee JS; Tsai CH; Lin KP; Wang HE; Chou TY; Tsai CM; Gelovani J; Liu RS
    Oncotarget; 2015 Apr; 6(11):8663-75. PubMed ID: 25796627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines.
    Oertel S; Thiemann M; Richter K; Weber KJ; Huber PE; Perez RL; Brons S; Bischof M; Kulozik AE; Ehemann V; Debus J; Blattmann C
    Radiat Oncol; 2011 Sep; 6():119. PubMed ID: 21933400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
    Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
    BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism.
    Mottet D; Pirotte S; Lamour V; Hagedorn M; Javerzat S; Bikfalvi A; Bellahcène A; Verdin E; Castronovo V
    Oncogene; 2009 Jan; 28(2):243-56. PubMed ID: 18850004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
    Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
    Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitor-loaded bone cement for advanced local treatment of osteosarcoma and chondrosarcoma.
    Tonak M; Becker M; Graf C; Eckhard L; Theobald M; Rommens PM; Wehler TC; Proschek D
    Anticancer Res; 2014 Nov; 34(11):6459-66. PubMed ID: 25368246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.